title: Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study.
abstract: OBJECTIVE
  Patients with natural killer T (NK/T) -cell lymphomas have poor survival outcome, and for this condition there is no optimal therapy. The purpose of this study was to design a prognostic model specifically for extranodal NK/T-cell lymphoma, which can identify high-risk patients who need more aggressive therapy.
  
  
  METHODS
  This multicenter retrospective study was comprised of 262 patients who were diagnosed with NK/T-cell lymphoma.
  
  
  RESULTS
  After a median follow-up duration of 51.2 months, 5-year overall survival rate in 262 patients was 49.5%. Prognostic factors for survival were "B" symptoms (P = .0003; relative risk, 2.202; 95% CI, 1.446 to 3.353), stage (P = .0006; relative risk, 2.366; 95% CI, 1.462 to 3.828), lactate dehydrogenase (LDH) level (P = .0005; relative risk, 2.278; 95% CI, 1.442 to 3.598), and regional lymph nodes (P = .0044; relative risk, 1.546; 95% CI, 1.009 to 2.367). Of 262 patients, 219 had complete information on four parameters. We identified four different risk groups: group 1, no adverse factor; group 2, one factor; group 3, two factors; and group 4, three or four factors. The new model showed a superior prognostic discrimination as compared with the International Prognostic Index (IPI). Notably, the distribution of patients was balanced when a new model was adopted (group 1, 27%; group 2, 31%; group 3, 20%; group 4, 22%), whereas 81% of patients were categorized as low or low-intermediate risks using IPI.
  
  
  CONCLUSIONS
  The newly proposed model for extranodal NK/T-cell lymphoma demonstrated a more balanced distribution of patients into four groups with better prognostic discrimination as compared with the IPI.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Jeeyun
authors.initials: J
authors.lastname: Lee
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
authors.forename: Yeon Hee
authors.initials: YH
authors.lastname: Park
authors.forename: Young H
authors.initials: YH
authors.lastname: Ko
authors.forename: Soo Mee
authors.initials: SM
authors.lastname: Bang
authors.forename: Jae Hoon
authors.initials: JH
authors.lastname: Lee
authors.forename: Dae Ho
authors.initials: DH
authors.lastname: Lee
authors.forename: Jooryung
authors.initials: J
authors.lastname: Huh
authors.forename: Sung Yong
authors.initials: SY
authors.lastname: Oh
authors.forename: Hyuk-Chan
authors.initials: HC
authors.lastname: Kwon
authors.forename: Hyo Jin
authors.initials: HJ
authors.lastname: Kim
authors.forename: Soon Il
authors.initials: SI
authors.lastname: Lee
authors.forename: Jung Han
authors.initials: JH
authors.lastname: Kim
authors.forename: Jinny
authors.initials: J
authors.lastname: Park
authors.forename: Seok Joong
authors.initials: SJ
authors.lastname: Oh
authors.forename: Kihyun
authors.initials: K
authors.lastname: Kim
authors.forename: Chulwon
authors.initials: C
authors.lastname: Jung
authors.forename: Keunchil
authors.initials: K
authors.lastname: Park
authors.forename: Won Seog
authors.initials: WS
authors.lastname: Kim
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D016001:Confidence Intervals; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007694:Killer Cells, Natural; D008207:Lymphatic Metastasis; D016399:Lymphoma, T-Cell / Q000175:diagnosis* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D009361:Neoplasm Invasiveness; D009669:Nose Neoplasms / Q000175:diagnosis* / Q000473:pathology; D016017:Odds Ratio; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis